ArticleNature cancer2024

BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models.

Ulrike Rauh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.